Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 555-562

  Marty, Francisco M ^a   Boeckh, Michael ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; GANCICLOVIR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; TASTE DISORDER; VIRUS LOAD; VIRUS SHEDDING;

EID: 82955247620     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.011     Document Type: Review

References (49)

1. L.B. Townsend, R.V. Devivar, S.R. Turk, M.R. Nassiri, and J.C. Drach Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D- ribofuranosyl)benzimidazoles J Med Chem 38 1995 4098 4105
2. R. Zou, J.C. Drach, and L.B. Townsend Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D- ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections J Med Chem 40 1997 802 810 (Pubitemid 27102586)
3. J. Chulay, K. Biron, L. Wang, M. Underwood, S. Chamberlain, L. Frick, S. Good, M. Davis, R. Harvey, and L. Townsend Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease Adv Exp Med Biol 458 1999 129 134
4. J.J. McSharry, A. McDonough, B. Olson, C. Talarico, M. Davis, and K.K. Biron Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94 Clin Diagn Lab Immunol 8 2001 1279 1281 (Pubitemid 33035768)
5. K.K. Biron, R.J. Harvey, S.C. Chamberlain, S.S. Good, A.A. Smith 3rd, M.G. Davis, C.L. Talarico, W.H. Miller, R. Ferris, and R.E. Dornsife Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action Antimicrob Agents Chemother 46 2002 2365 2372 (Pubitemid 34793437)
6. S.L. Williams, C.B. Hartline, N.L. Kushner, E.A. Harden, D.J. Bidanset, J.C. Drach, L.B. Townsend, M.R. Underwood, K.K. Biron, and E.R. Kern In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses Antimicrob Agents Chemother 47 2003 2186 2192 (Pubitemid 36753570)
7. G.W. Koszalka, N.W. Johnson, S.S. Good, L. Boyd, S.C. Chamberlain, L.B. Townsend, J.C. Drach, and K.K. Biron Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication Antimicrob Agents Chemother 46 2002 2373 2380 (Pubitemid 34793438)
8. M.R. Underwood, R.J. Harvey, S.C. Stanat, M.L. Hemphill, T. Miller, J.C. Drach, L.B. Townsend, and K.K. Biron Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product J Virol 72 1998 717 725 (Pubitemid 28048891)
9. V.C. Emery, and A.F. Hassan-Walker Focus on new drugs in development against human cytomegalovirus Drugs 62 2002 1853 1858
10. M.C. Baek, P.M. Krosky, Z. He, and D.M. Coen Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position J Biol Chem 277 2002 29593 29599 (Pubitemid 41079248)
11. P.M. Krosky, M.C. Baek, and D.M. Coen The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress J Virol 77 2003 905 914 (Pubitemid 36055512)
12. S. Hamirally, J.P. Kamil, Y.M. Ndassa-Colday, A.J. Lin, W.J. Jahng, M.C. Baek, S. Noton, L.A. Silva, M. Simpson-Holley, and D.M. Knipe Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress PLoS Pathog 5 2009 e1000275
13. M.N. Prichard, W.J. Britt, S.L. Daily, C.B. Hartline, and E.R. Kern Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis J Virol 79 2005 15494 15502 (Pubitemid 43032331)
14. S. Chou, L.C. Wechel, and G.I. Marousek Cytomegalovirus UL97 kinase mutations that confer maribavir resistance J Infect Dis 196 2007 91 94 (Pubitemid 46982742)
15. M.N. Prichard Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir Rev Med Virol 19 2009 215 229
16. R.K. Avery, F.M. Marty, L. Strasfeld, I. Lee, A. Arrieta, S. Chou, W. Tatarowicz, and S. Villano Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients Transpl Infect Dis 12 2010 489 496
17. L. Strasfeld, I. Lee, W. Tatarowicz, S. Villano, and S. Chou Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir J Infect Dis 202 2010 104 108
18. G. Komazin, R.G. Ptak, B.T. Emmer, L.B. Townsend, and J.C. Drach Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs Nucleosides Nucleotides Nucleic Acids 22 2003 1725 1727 (Pubitemid 37139484)
19. S. Chou, G.I. Marousek, A.E. Senters, M.G. Davis, and K.K. Biron Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir J Virol 78 2004 7124 7130 (Pubitemid 38781550)
20. M.N. Prichard, D.C. Quenelle, D.J. Bidanset, G. Komazin, S. Chou, J.C. Drach, and E.R. Kern Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice Virol J 3 2006 18
21. S. Chou Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir Antimicrob Agents Chemother 53 2009 81 85
22. J.M. Reitsma, J.P. Savaryn, K. Faust, H. Sato, B.D. Halligan, and S.S. Terhune Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest Cell Host Microbe 9 2011 103 114
23. J.P. Kamil, and D.M. Coen HATs on for drug resistance Cell Host Microbe 9 2011 85 87
24. L.H. Wang, R.W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M.B. Wire Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects Antimicrob Agents Chemother 47 2003 1334 1342 (Pubitemid 36368594)
25. J.P. Lalezari, J.A. Aberg, L.H. Wang, M.B. Wire, R. Miner, W. Snowden, C.L. Talarico, S. Shaw, M.A. Jacobson, and W.L. Drew Phase I. dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding Antimicrob Agents Chemother 46 2002 2969 2976
26. J.P. Lalezari, W.L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P.E. Fisher, K. Cundy, J. Hannigan, and J.C. Martin (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue J Infect Dis 171 1995 788 796
27. J.P. Lalezari, R.J. Stagg, B.D. Kuppermann, G.N. Holland, F. Kramer, D.V. Ives, M. Youle, M.R. Robinson, W.L. Drew, and H.S. Jaffe Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial Ann Intern Med 126 1997 257 263
28. D.R. Goldwater, C. Dougherty, M. Schumacher, and S.A. Villano Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults Antimicrob Agents Chemother 52 2008 1794 1798 (Pubitemid 351614674)
29. J. Trofe, L. Pote, E. Wade, E. Blumberg, and R.D. Bloom Maribavir a novel antiviral agent with activity against cytomegalovirus Ann Pharmacother 42 2008 1447 1457
30. M. Pollack, J. Heugel, H. Xie, W. Leisenring, J. Storek, J.A. Young, M. Kukreja, R. Gress, M. Tomblyn, and M. Boeckh An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients Biol Blood Marrow Transplant 17 2011 664 673
31. D.J. Winston, J.A. Young, V. Pullarkat, G.A. Papanicolaou, R. Vij, E. Vance, G.J. Alangaden, R.F. Chemaly, F. Petersen, and N. Chao Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study Blood 111 2008 5403 5410
32. P. Ljungman, R. de La Camara, N. Milpied, L. Volin, C.A. Russell, A. Crisp, and A. Webster Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants Blood 99 2002 3050 3056 (Pubitemid 34525398)
33. F.M. Marty, P. Ljungman, G.A. Papanicolaou, D.J. Winston, R.F. Chemaly, L. Strasfeld, J.A. Young, T. Rodriguez, J. Maertens, and M. Schmitt Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial Lancet Infect Dis 11 2011 284 292
34. F.M. Marty, J. Bryar, S.K. Browne, T. Schwarzberg, V.T. Ho, I.V. Bassett, J. Koreth, E.P. Alyea, R.J. Soiffer, and C.S. Cutler Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis Blood 110 2007 490 500 (Pubitemid 47105386)
35. J.D. Meyers, N. Flournoy, and E.D. Thomas Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 153 1986 478 488 (Pubitemid 16135651)
36. P. Ljungman, P. Griffiths, and C. Paya Definitions of cytomegalovirus infection and disease in transplant recipients Clin Infect Dis 34 2002 1094 1097 (Pubitemid 34289682)
37. C. Junghanss, M. Boeckh, R.A. Carter, B.M. Sandmaier, M.B. Maris, D.G. Maloney, T. Chauncey, P.A. McSweeney, M.T. Little, L. Corey, and R. Storb Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood 99 2002 1978 1985 (Pubitemid 34525478)
38. Author ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients. 2009 Available from: http://ir.viropharma.com/ releasedetail.cfm?ReleaseID=543167.
39. S.K. Swan, W.B. Smith, T.C. Marbury, M. Schumacher, C. Dougherty, B.A. Mico, and S.A. Villano Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment J Clin Pharmacol 47 2007 209 217 (Pubitemid 46146487)
40. J.M. Goodrich, R.A. Bowden, L. Fisher, C. Keller, G. Schoch, and J.D. Meyers Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 118 1993 173 178 (Pubitemid 23034801)
41. M. Boeckh, T.A. Gooley, D. Myerson, T. Cunningham, G. Schoch, and R.A. Bowden Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 88 1996 4063 4071 (Pubitemid 26383133)
42. P. Griffiths, R. Whitley, D.R. Snydman, N. Singh, and M. Boeckh Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007 Herpes 15 2008 4 12
43. H. Nakamae, K.A. Kirby, B.M. Sandmaier, L. Norasetthada, D.G. Maloney, M.B. Maris, C. Davis, L. Corey, R. Storb, and M. Boeckh Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 15 2009 694 703
44. J.D. Meyers, P. Ljungman, and L.D. Fisher Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia J Infect Dis 162 1990 373 380 (Pubitemid 20239951)
45. M. Boeckh, R.A. Bowden, J.M. Goodrich, M. Pettinger, and J.D. Meyers Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation Blood 80 1992 1358 1364
46. D. Gor, C. Sabin, H.G. Prentice, N. Vyas, S. Man, P.D. Griffiths, and V.C. Emery Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease Bone Marrow Transplant 21 1998 597 605 (Pubitemid 28138259)
47. V.C. Emery, C.A. Sabin, A.V. Cope, D. Gor, A.F. Hassan-Walker, and P.D. Griffiths Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation Lancet 355 2000 2032 2036 (Pubitemid 30339241)
48. V.C. Emery, A.V. Cope, E.F. Bowen, D. Gor, and P.D. Griffiths The dynamics of human cytomegalovirus replication in vivo J Exp Med 190 1999 177 182 (Pubitemid 29354911)
49. M. Boeckh, G.M. Gallez-Hawkins, D. Myerson, J.A. Zaia, and R.A. Bowden Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture Transplantation 64 1997 108 113 (Pubitemid 27327209)